Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA

被引:19
作者
Levy, Y
Gilburd, B
George, J
Del Papa, N
Mallone, R
Damianovich, M
Blank, M
Radice, A
Renaudineau, Y
Youinou, P
Wiik, A
Malavasi, F
Meroni, PL
Shoenfeld, Y [1 ]
机构
[1] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer & Sackler Fac Med, Dept Med B, IL-52621 Tel Hashomer, Israel
[2] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer & Sackler Fac Med, Autoimmune Dis Res Unit, IL-52621 Tel Hashomer, Israel
[3] Univ Milan, IRCCS, Policlin Milan, Ist Med Interna Malattie Infett & Immunopatol, I-20122 Milan, Italy
[4] Univ Turin, Dipartimento Genet Biol & Biochim, Lab Biol Cellulare, I-10126 Turin, Italy
[5] S Carlo Hosp, Dipartimento Nefrol, I-20153 Milan, Italy
[6] Ctr Hosp Reg & Univ, Immunol Lab, F-29200 Brest, France
[7] Statens Serum Inst, DK-2300 Copenhagen, Denmark
关键词
anti-endothelial antibodies; autoimmunity; mAb;
D O I
10.1093/intimm/10.7.861
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The IgG fraction of human anti-endothelial cell antibodies (AECA) obtained from a patient with Wegener's granulomatosis was used as immunogen to raise AECA mAb in mice selected among those which developed vasculitis-like lesions after immunization. Three mAb (BGM, 3C8 and 7G2), selected by cyto-ELISA and flow cytometry analyses, featured a specific reactivity with human umbilical vein endothelial cells (HUVEC) and the mouse endothelial cell line H5V; on the contrary, HEp2 cells, the murine melanoma B16 cell line, the extracellular matrix as well as several other antigens tested were not recognized. BGM mAb, an IgG3 precipitating a 70 kDa structure from HUVEC, was able to induce endothelial cells to secrete amounts of IL-6 significantly higher than irrelevant controls or mAb binding different endothelial antigens (i,e. CD31, CD29, ICAM-1 and HLA class I). BGM mAb induced significant levels of antibody-dependent cell cytotoxicity(13 +/- 2.5 versus 0.6 +/- 0.03%), To the best of our knowledge, BGM is the first murine mAb specific for human endothelial cells generated by idiotypic manipulation; secondly, its biological properties further support the notion of a pathogenic role for AECA in autoimmune-mediated diseases.
引用
收藏
页码:861 / 868
页数:8
相关论文
共 33 条
[1]   INDUCTION OF PRIMARY ANTIPHOSPHOLIPID SYNDROME IN MICE BY IMMUNIZATION WITH A HUMAN MONOCLONAL ANTICARDIOLIPIN ANTIBODY (H-3) [J].
BAKIMER, R ;
FISHMAN, P ;
BLANK, M ;
SREDNI, B ;
DJALDETTI, M ;
SHOENFELD, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (05) :1558-1563
[2]  
BLANK M, 1995, CLIN EXP IMMUNOL, V102, P120
[3]   INDUCTION OF ANTIPHOSPHOLIPID SYNDROME IN NAIVE MICE WITH MOUSE LUPUS MONOCLONAL AND HUMAN POLYCLONAL ANTICARDIOLIPIN ANTIBODIES [J].
BLANK, M ;
COHEN, J ;
TODER, V ;
SHOENFELD, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) :3069-3073
[4]   THE IMPORTANCE OF THE PATHOGENIC 16/6-IDIOTYPE IN THE INDUCTION OF SLE IN NAIVE MICE [J].
BLANK, M ;
KRUP, M ;
MENDLOVIC, S ;
FRICKE, H ;
MOZES, E ;
TALAL, N ;
COATES, ARM ;
SHOENFELD, Y .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1990, 31 (01) :45-52
[5]   INDUCTION OF SLE-LIKE DISEASE IN NAIVE MICE WITH A MONOCLONAL ANTI-DNA ANTIBODY DERIVED FROM A PATIENT WITH POLYMYOSITIS CARRYING THE 16/6 ID [J].
BLANK, M ;
MENDELOVIC, S ;
MOZES, E ;
SHOENFELD, Y .
JOURNAL OF AUTOIMMUNITY, 1988, 1 (06) :683-691
[6]   INDUCTION OF EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME ASSOCIATED WITH SLE FOLLOWING IMMUNIZATION WITH HUMAN MONOCLONAL PATHOGENIC ANTI-DNA IDIOTYPE [J].
BLANK, M ;
KRAUSE, I ;
BENBASSAT, M ;
SHOENFELD, Y .
JOURNAL OF AUTOIMMUNITY, 1992, 5 (04) :495-509
[7]   IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro - Induction of adhesion molecule expression and involvement of endothelium-derived cytokines [J].
Carvalho, D ;
Savage, COS ;
Black, CM ;
Pearson, JD .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :111-119
[8]  
COHEN J, 1994, CLIN EXP IMMUNOL, V97, P181
[9]  
Damianovich M, 1996, J IMMUNOL, V156, P4946
[10]  
DEAGLIO S, 1997, IN PRESS J IMMUNOL